Non-Small Cell Lung Cancer Coverage from Every Angle

Suresh S. Ramalingam, MD, on Managing Pyrexia With Dabrafenib/Trametinib in Advanced NSCLC

Posted: Monday, June 10, 2019

What is your protocol when a patient with advanced NSCLC who is receiving dabrafenib/trametinib develops a grade 1 or 2 fever or higher?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.